Michaela Arndt (CEO at Heidelberg Immunotherapeutics) spoke at the BioRN Lounge on October 25, 2022 sharing latest updates on the development of innovative immunotherapeutics for the treatment of viral diseases and cancer. As a clinical stage biopharmaceutical company and spin-off of the NCT (National Center for Tumor Diseases Heidelberg), the growth of Heidelberg Immunotherapeutics has been so far very dynamic.
Michaela shared a personal prospective of this journey from bench to bed, from lab to patients and from being a scientist to become an entrepreneur. She shared some tips that might become useful for others while enduring the same journey.
Social media posts >>